MedTrace Logo

Interaction of BI 691751 With Itraconazole

NCT02044393 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-16

Study results available
· View outcomes & findings →

Summary

Investigation of the relative bioavailability of a single dose of BI 691751 when given alone and together with itraconazole; safety and tolerability

Conditions

  • Healthy

Interventions

DRUG

itraconazole

multiple doses of itraconazole given as capsules

DRUG

BI 691751

single dose BI 691751 given as tablet

DRUG

BI 691751

single dose BI 691751 given as tablet

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02044393 on ClinicalTrials.gov